Stockscreener 앱 받기
0.4499
1.67%
0.0074
시간 외 거래:
.43
-0.0199
-4.42%
Nextcure Inc 주식(NXTC)의 최신 뉴스
NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks
NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
NextCure, Inc. SEC 10-Q Report - TradingView
NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan
NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
It’s Worth A Gamble To Have A Position In Applied Therapeutics Inc (NASDAQ: APLT) At $0.32. - Marketing Sentinel
NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks
NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia
NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India
NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia
NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa
NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
2 Net Current Asset Value Stocks to Consider - GuruFocus.com
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN
NextCure Reports 2024 Financials and Strategic Progress - TipRanks
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times
NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq
Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan
NextCure Inc. (NXTC) reports earnings - qz.com
Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada
Ventia Strengthens Leadership with New Company Secretary Appointment - MSN
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance
Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN
0.39%
3.66%
자본화:
|
볼륨(24시간):